MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinson’s"

  • 2025 International Congress

    Refining the International Parkinson and Movement Disorder Society Parkinson’s Disease Psychosis Rating Scale (MDS-PDPRS): Cognitive Interview Results from an International Study

    M. Tosin, T. Mestre, G. Stebbins, G. Mangone, S. Videmsky, S. Ali, D. Aarsland, J. Goldman, T. Khoo, S. Lewis, P. Martinez-Martin, O. Ojo, J. Pagonabarraga, A. Schrag, D. Weintraub, C. Goetz (Chicago, USA)

    Objective: To assess the face and content validity of the International Parkinson and Movement Disorder Society Parkinson’s Disease Psychosis Rating Scale (MDS-PDPRS), a new under-developing Clinical…
  • 2025 International Congress

    Long-Term Effects of Telerehabilitation on Functional Mobility and Quality of Life in Parkinson’s Disease: A Systematic Review

    A. Elsayed, D. W. Ismail, H. Elshazly, Y. M.HUSSEINY, S. Elrobeigi, Y. Hamdi, M. M. Elsayed (Mansoura, Egypt)

    Objective: To evaluate the long-term effects of telerehabilitation on functional mobility and quality of life (QoL) in individuals with Parkinson’s disease (PD) and determine its…
  • 2025 International Congress

    Efficacy of Rifaximin as an Adjunct Treatment for Levodopa induced dyskinesia: Preliminary Results

    K. Salinas-Barboza, J. Altamirano, L. Navarro-Roa, M. Rodriguez-Violante (Ciudad de México, Mexico)

    Objective: To evaluate the efficacy of rifaximin as an adjunct treatment for LID (levodopa induced dyskinesia) in patients with PD through a randomized, double-blind, placebo-controlled…
  • 2025 International Congress

    Validation of a quantitative test using kinesiological evaluation of upper extremity movements in patients with Parkinson’s disease: A pilot study.

    A. Castillo-Ivon, A. Montes-Ugalde, V. Bueyes-Roiz, C. Hernandez-Arenas, P. Velasco-Acosta, L. Anaya-Campos, I. Quiñones-Uriostegui, J. Quinzaños-Fresnedo (Mexico City, Mexico)

    Objective: To establish the validity of an upper extremity kinesiological assessment in patients with Parkinson's disease as a complementary tool to clinical instruments. Background: Parkinson's…
  • 2025 International Congress

    Characteristics and Trends of Parkinson’s Disease Patients Receiving Deep Brain Stimulation: Insights From a US All-Payer Health Administrative Claims Database

    W. Zhang, M. Bharadwaz, A. Gabriel, J. Weber, M. Frick, A. Yaldo, C. Gøtzsche, T. Machewitz, J. Lott (Whippany, USA)

    Objective: To describe sociodemographics, treatment patterns, and costs among Parkinson’s patients who received deep brain stimulation (DBS) in the United States (US). Background: Parkinson’s disease…
  • 2025 International Congress

    Prevalence of Central Pain in Parkinson’s Disease: A Systematic Review and Meta-analysis

    K. Vieira, L. Pereira, G. Trevisan (Santa Maria, Brazil)

    Objective: In this systematic review and meta-analysis, we aimed to evaluate the prevalence of central pain and how this symptom may affect the patient's quality…
  • 2025 International Congress

    Exploring the ubiquitome in Parkinson’s Disease

    A. Yeung, SA. Cobbold, M. Li, GK. Smyth, L. Wang, JR. Han, IKL. Tan, M. Bahlo, AH. Evans, D. Komander, S. Masaldan, G. Dewson (Melbourne, Australia)

    Objective: To explore the role of ubiquitin signalling defects in Parkinson’s Disease. Background: Defects in ubiquitin signalling have been implicated in the pathogenesis of neurodegenerative…
  • 2025 International Congress

    Apolipoprotein E ɛ4-allele and Amygdala Atrophy in Parkinson’s Disease: A Preliminary Longitudinal Analysis from the ONDRI Cohort

    U. Saeed, R. Bartha, M. Binns, S. Black, D. Grimes, R. Hegele, C. Marras, . Rogaeva, M. Lang, M. Masellis (Toronto, Canada)

    Objective: To investigate the association of apolipoprotein E ɛ4-allele (APOE-ε4) with amygdala volumes longitudinally in Parkinson’s disease (PD). Background: APOE-ε4 is a genetic risk factor…
  • 2025 International Congress

    Exploring Neuroprotective Role of Natural Compound by Targeting c-Abl Kinase in Parkinson’s Disease

    D. Khatri (Chandwaji, Jaipur, India)

    Objective: To explore c-Abl kinase activation and neuron death pathway in Parkinson’s Disease (PD) mouse model. Assess neuroprotection natural compounds, Rosmarinic acid (RA) with proven…
  • 2025 International Congress

    Evaluation of Perfusion, Iron Deposition, and Neuromelanin MRI Biomarkers Following Mesenchymal Stem Cell Treatment in a Phase 2 Parkinson’s Disease Trial

    J. Martinez-Lemus, E. Tharp, T. Ellmore, T. Thomas, C. Green, J. Suescun, C. Onuigbo, T. Le, E. Rodarte-Rascon, R. Ritter Iii, M. Schiess (Houston, USA)

    Objective: Evaluate the effects of allogeneic bone marrow-derived mesenchymal stem cell (allo-hMSC) infusions on neuroimaging biomarkers in patients with Parkinson’s disease (PD) using different MRI…
  • « Previous Page
  • 1
  • …
  • 70
  • 71
  • 72
  • 73
  • 74
  • …
  • 436
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley